Nektar Therapeutics has initiated the first two global registrational trials in its Phase 3 ZENITH AD programme for rezp...
Akeso has dosed the first patient in a Phase II clinical study evaluating AK146D1 in combination with ivonescimab for ad...
Halozyme Therapeutics has entered a global collaboration and licence agreement with Incyte to evaluate additional subcut...
Akeso has launched a Phase II clinical study in the United States evaluating a cadonilimab-based combination regimen for...
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355, also known as SP0...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration for ...
Drug development is approaching a significant inflection point. Advances in induced pluripotent stem cells (iPSCs), orga...
US-based Organon, a global healthcare company with deep expertise in biosimilars, and Korea's Samsung Bioepis have annou...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
Kelun-Biotech has reported positive Phase III results for sacituzumab tirumotecan, also known as sac-TMT or SKB264/MK-28...
Novo Nordisk has reported interim Phase III FRONTIER4 extension data for denecimig, also known as Mim8, in people with h...
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administrati...
BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim have announced the launch of a new research t...
Artificial intelligence is rapidly reshaping the way biopharma companies discover, develop, and manufacture medicines. H...
As antibody-drug conjugates (ADCs) transition from a promising therapeutic modality to a cornerstone of precision oncolo...
As antibody-drug conjugates (ADCs), bispecific antibodies and other advanced biologics redefine the global therapeutics ...
The rapid expansion of in vivo gene therapy is reshaping expectations for viral vector manufacturing, placing greater em...
ADCs continue to represent a major growth area for drug developers, with the market projected to reach $69B by 20291. As...
Mubadala Bio has announced the signing of a licencing and supply agreement with Biosidus, a leading biotechnology compan...
Innovent Biologics has dosed the first patient in the Chinese pivotal Phase III TriadicMM-1 trial of IBI3003 for relapse...
During BIO 2026 in San Diego, BioSpectrum Asia spoke with Kurt Imhof, Senior Vice President, Policy & Public Affairs...
As obesity treatment evolves beyond weight loss toward comprehensive cardiometabolic disease management, pharmaceutical ...
Few therapeutic areas have witnessed the level of progress achieved in HIV over the past three decades...
Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
